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Aim: Resistin plays a role in the pathogenesis of coronary artery disease and is related to mortality and morbidity through a number
of mechanisms. We hypothesize that plasma resistin levels are increased in the presence of ischemia, as measured by GATED singlephoton emission computed tomography myocardial perfusion scintigraphy (SPECT MPS), in comparison with nonischemic subjects.
Materials and methods: Fasting intravenous blood samples of patients were drawn before a stress test. An ELISA kit was used for
the assays. All patients underwent a technetium 99m-sestamibi GATED SPECT MPS study with a 1-day stress-rest protocol. Images
were analyzed visually and patients were assessed as ischemic or nonischemic. Resistin levels were presented as medians (25th–75th
percentiles) and were compared using the Mann–Whitney U test.
Results: Plasma resistin levels were higher in the ischemic group (n = 47) than in the nonischemic group (n = 67) [9.04 µmol/L
(6.27–11.8 µmol/L) vs. 3.56 µmol/L (0.39–7.93 µmol/L), respectively; P < 0.001). We showed that plasma resistin levels (OR = 1.26,
95% CI: 1.13–1.41; P < 0.001) and METs (OR = 0.82, 95% CI: 0.70–0.92; P = 0.021) were independent predictors of ischemia. No linear
correlation was found between plasma resistin levels and GATED SPECT or stress test parameters.
Conclusion: Increased baseline resistin levels are independently related to presence of ischemia but are not related to the extent or
severity of ischemia, or other functional parameters such as poststress ejection fraction, end systolic, and end diastolic volumes.
Key words: Resistin, myocardial perfusion scintigraphy, ischemia

1. Introduction
Resistin aggravates atherosclerosis through the stimulation
of monocytes, endothelial cells, and vascular smooth
muscle cells to induce vascular inflammation in humans
and animal models (1–3). Serum resistin is a biological
marker of coronary artery disease (CAD) and restenosis,
especially in patients with type 2 diabetes (4,5).
However, several clinical studies have demonstrated
that resistin is an inflammatory cytokine, although not
directly related to atherosclerosis, metabolic syndrome, or
CAD (6,7). Other studies have shown that serum resistin
is correlated with hs-CRP, inflammatory processes, age,
and decreased renal function, but is not directly associated
with severe coronary stenosis or vascular events (5,8). No
relationship has been shown between resistin and type 2
diabetes in Korean patients (9).
As described above, results regarding the clinical
importance of resistin are controversial and only one large
* Correspondence: drmustafayildirim@yahoo.com
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cross-sectional study has directly evaluated the relationship
between resistin and cardiac functional status using stress
echocardiography (10). We hypothesize that plasma
resistin levels are increased in the presence of ischemia
compared with nonischemic subjects when using GATED
single-photon emission computed tomography myocardial
perfusion scintigraphy (SPECT MPS). Accordingly, this is
the second study to report a correlation between resistin
and functional status of myocardium, but using a different
method.
2. Materials and methods
2.1. Study population
This study included 114 consecutive patients [42 males
(36.8%), 72 females (63.2%), mean age 57 ± 11 years]
with ischemic (n = 47) and nonischemic (n = 67) results
based on GATED myocardial SPECT. None of the patients
had cardiac valve disease, cardiomyopathy, malignant
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arrhythmias, acute or chronic liver disease, renal failure,
suspected pregnancy, or were breastfeeding at the time of
inclusion in the study. Patients with a fixed defect, history
of myocardial infarction, bypass, or revascularization
were excluded. GATED SPECT MPS was performed to
diagnose CAD. A detailed history, including risk factors,
current medications, body mass index (BMI), waist
circumference, blood pressure before and after exercise
test, metabolic equivalents (METs), and baseline heart rate
was obtained from all patients. Fasting intravenous (i.v.)
blood samples of patients were drawn before the stress
test. All patients underwent technetium 99m-sestamibi
(99mTc-sestamibi) GATED SPECT MPS study with a
1-day stress-rest protocol. All subjects provided informed
consent prior to enrollment in the study and the study was
approved by the local ethics committee.
2.2. Imaging protocol
Blood pressure, heart rate, and EKG of the subjects were
monitored during the test. Test endpoints were physical
exhaustion, anginal complaints, dyspnea, a significant
decrease in blood pressure greater than 10 mmHg, or
achievement of maximal age-related heart rate. In other
patients, a pharmacological stress test was performed
by i.v. administration of either adenosine (0.14 mg/kg/
min for 6 min) or dobutamine (up to a maximum dose
of 40 µg/kg/min in 15 min) until the required age-related
heart rate was reached. The test was performed using a
1-day protocol. Beta-blockers and calcium antagonists
were discontinued for 48 h and long-acting nitrates
were discontinued for 24 h before GATED myocardial
SPECT. Caffeine- and theophylline-containing foods/
medications and tobacco were discontinued for 1 day prior
to the study. At peak exercise, 296–370 MBq (8–10 mCi)
of 99mTc-Sestamibi was injected intravenously. Exercise
continued for another 1–2 min after injection of the tracer.
Resting images were obtained 3–4 h after stress imaging
with a 3-fold injection of the tracer. The images were
acquired 45 min after stress injection and 60 min after rest
injection, with a single-headed gamma camera (E-cam
Single Head Gamma Camera, Siemens, Germany) with
all-purpose high-resolution collimators. The studies were
prefiltered with a Butterworth filter and back-projected
with a ramp filter. After reconstruction, the data were
displayed as tomographic slices and bull’s eye maps (polar
plots), and images were visually evaluated. Post-stress
GATED parameters [ejection fraction (EF), end systolic/
end diastolic volumes (ESV/EDV), and automatic stress
defect scores (SDS)] were recorded.
2.3. Resistin measurements
Serum specimens were separated from whole blood
samples by centrifugation at 5000 rpm for 10 min and
stored at –20 °C until assay time. Hemolytic and lipemic
serum samples were excluded from the study. An ELISA

kit was used for the assays (BioVendor, Czech Republic),
which were performed with the BioTek Epoch microplate
reader (BioTek Instruments, Inc. Winooski, VT, USA).
Before the assay procedure, all samples were brought to
room temperature and mixed carefully to avoid foam
development. Standards, controls, dilution buffer as blank,
and samples (100 μL each) were added to the wells. The
plate was incubated at room temperature for 1 h on an
orbital shaker at 300 rpm. Wells were washed 3 times with
a wash solution (0.35 μL per well). Biotin-labeled antibody
solution (100 μL) was added to each well and the plate
was incubated at room temperature for 1 h on an orbital
shaker at 300 rpm. After repeating the washing process,
streptavidin-HRP (100 μL) was added to each well. The
incubation and washing processes were repeated. After
these steps, a substrate solution (100 μL) was added to
each well. The plate was covered with aluminum foil to
avoid sunlight and incubated at room temperature for
10 min. Color development was stopped by adding stop
solution (100 μL) to each well. The absorbance of each
well was determined by using a microplate reader set to
450 nm with the reference wavelength set to 630 nm. The
absorbance at 630 nm was subtracted from that at 450 nm.
The standard curve was as predicted and control results
were in the appropriate range.
2.4. Statistical analysis
Statistical analyses were performed using the PASW 18
statistical software (version 18.0 for Windows; SPSS Inc.,
Chicago, IL, USA). Normality analyses of continuous
variables were performed with histogram curves.
Continuous variables are presented as means ± standard
deviation or medians (25th–75th percentiles) and when
compared between the 2 groups, an independent samples
t-test and Mann–Whitney U test were performed.
Spearman’s test was performed to identify linear
correlations between 2 continuous variables. Categorical
variables were compared between the 2 groups using
chi-square tests and presented as frequencies and
percentages. Receiver operating curve (ROC) analyses
were performed to determine the cut-off value of resistin
levels for estimating ischemia. Univariate and multivariate
logistic regression analyses were performed to estimate
independent predictors of ischemia based on MPS. A
forward stepwise logistic regression method was used
and P values less than 0.05 were considered to indicate
statistical significance.
3. Results
Patient characteristics are presented in Table 1. Sex
distribution was similar in the 2 groups; 21 males (44.7%)
in the ischemic group and 21 males (31.3%) in the
nonischemic group (P = 0.146). Mean age was 60 ± 10 years
in the ischemic group and 55 ± 11 years in the nonischemic
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Table 1. Characteristics of the patients.
Nonischemic patients
(n = 67)

Ischemic patients
(n = 47)

P

55 ± 11

60 ± 10

0.015

21 (31)

21 (44)

0.146

Body mass index (kg/m )

30.2 ± 4.7

30 ± 4.2

0.841

Hypertension (n, %)

38 (56.7)

30 (63.8)

0.446

Diabetes (n, %)

11 (16.4)

11 (23.4)

0.299

Hyperlipidemia (n, %)

15 (22.4)

11 (23.4)

0.899

Resistin (µmol/L)

3.56 (0.39–7.93)

9.04 (6.27–11.8)

<0.001

Current smoking (n, %)

14 (20.9)

10 (21.3)

0.961

Beta blocker

13(20)

15(31.9)

0.151

Calcium channel blocker

12(18.5)

11(23.4)

0.523

Antiaggregant

15(23.1)

21(44.7)

0.016

ACE inhibitor

19(29.2)

9(19.1)

0.224

Digital

0(0)

1(2.1)

0.237

Nitrate

0(0)

6(12.8)

0.003

Oral antidiabetic or insulin

8(11.9)

8(17.0)

0.442

Antihyperlipidemic

8(11.9)

8(17.0)

0.442

Systolic blood pressure (mmHg)

124.3 ± 16.8

123.6 ± 15.3

0.819

Diastolic blood pressure (mmHg)

73.5 ± 8.4

73.8 ± 8.0

0.875

Waist circumference (cm)

101.3 ± 10.1

99.7 ± 11.6

0.428

Age (years)
Sex (male; n, %)
2

Medication (n, %)

group (P = 0.015). Mean MET levels were 7.9 ± 2.7 in the
ischemic group and 10 ± 2.8 in the nonischemic group (P
< 0.001). Frequencies of nitrate and antiaggregant use were
higher in the ischemic group.
Plasma resistin levels were higher in the ischemic
group than in the nonischemic group and median values

were 9.04 µmol/L (6.27–11.8 µmol/L) and 3.56 µmol/L
(0.39–7.93 µmol/L), respectively (P < 0.001).
There was no linear correlation between plasma
resistin levels and both GATED parameters (EF, ESV, and
EDV) and stress test (automatically calculated SSS and
SDS) parameters (Table 2).

Table 2. Correlations of ADMA levels between both GATED and stress parameters.
Plasma resistin levels
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r

P

Stress defect score

–0.041

0.667

Summed difference score

–0.165

0.079

Ejection fraction

0.151

0.128

End systolic volume

–0.108

0.283

End diastolic volume

–0.062

0.537
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A 0.80 sensitivity and 0.57 specificity were obtained
for a 5.4 µmol/L cut-off value of resistin in ROC analyses
(AUC = 0.788; P < 0.001; Figure).
In univariate logistic regression analyses, plasma
resistin level (OR = 1.3, 95% CI: 1.2–1.4; P < 0.001), age (OR
= 1.04, 95% CI: 1.008–1.082; P = 0.018), and METs (OR
= 0.773, 95% CI 0.67–0.90; P = 0.001) were independent
predictors of ischemia according to GATED SPECT MPS.
In age- and METs-adjusted multivariate analyses, plasma
resistin level remained independently related to ischemia
(OR = 1.3, 95% CI: 1.1–1.4; P < 0.001). METs were also
related to ischemia (OR = 0.82, 95% CI: 0.70–0.97; P =
0.021; Table 3).
4. Discussion
Our results showed plasma resistin levels were higher in
the ischemic group, and that an increased resistin level
was an independent predictor of ischemia presence when
adjusted for age and METs, but did not correlate adequately
with severity of ischemia, EF, ESV, or EDV. A 5.4 µmol/L
cut-off value for resistin yielded strong sensitivity but
moderate specificity.
To date, only one study has reported the functional
status of myocardium in stable CAD. The authors measured
ROC Curve

1.0

Sensitivity

0.8
0.6
0.4
0.2
0.0

0.0

0.2

0.4
0.6
0.8
1.0
1 - Specificity
Diagonal segments are produced by ties.

Figure. We obtained a 0.80 sensitivity and 0.57 specificity for cutoff value of resistin of 5.4 in ROC analyses (AUC = 0.788; P <
0.001).

serum resistin after a treadmill exercise test by performing
stress echocardiography. The frequency of inducible
ischemia was significantly higher in the highest resistin
quartile. After adjusting the model for inflammatory
markers, resistin remained associated with inducible
ischemia (10). Yaseen et al. grouped elderly patients in
ischemic and nonischemic groups, as well as diabetic and
nondiabetic groups. Ischemic geriatric patients in both
the diabetic and nondiabetic groups had significantly
higher plasma resistin levels (11). We also investigated
the functional status of myocardium in stable CAD using
a different method than GATED MPS. We obtained
similar results as in the 2 above-mentioned studies, which
indicates that resistin could be an independent predictor
of ischemia.
In addition to studies on the functional status of
myocardium, others have evaluated the anatomical status
of coronary arteries. Kręcki et al. compared resistin
levels between 3 vessel diseases and controls; the mean
resistin levels were similar in the 2 groups (12). Pilz et al.
reported that resistin was not an independent risk factor
for angiographic cardiovascular disease (13). Hoefle et al.
were in agreement with the last 2 authors and reported no
significant increase in plasma resistin levels in coronary
stenosis (14). On et al. found higher resistin levels in CAD
in type 2 diabetes mellitus (15). In another study, the
severity of CAD was represented as the number of stenoses
in coronaries. Resistin levels were higher in angiographic
CAD, and after adjusting for age and sex, resistin levels
remained high, which correlated with the number of
stenotic segments; the authors suggested resistin to be
related to the presence and severity of the disease (16). In
contrast, our results suggest that resistin is related only to
the presence of the disease.
Previous studies did not report a resistin cut-off level
or related diagnostic value for estimating CAD or ischemic
heart disease. We revealed that resistin has a high sensitivity
for ischemia when 5.4 µmol/L is used as the cut-off.
In conclusion, increased plasma resistin levels are
independently related to the presence of ischemia but not
to its extent, severity, or other functional parameters, such
as poststress ejection fraction and end systolic/diastolic
volumes. An assay of plasma resistin can be considered a
highly sensitive test when a cut-off value of 5.4 µmol/L is used.

Table 3. Predictors of ischemia on MPS. (Logistic regression analyses, method: forward stepwise LR).
Univariate analyses

Multivariate analyses

OR

95% CI for OR

P

OR

95% CI for OR

P

Age (year)

1.04

1.01–1.08

0.018

-

-

-

Plasma resistin (µmol/L)

1.28

1.15–1.42

<0.001

1.26

1.13–1.41

<0.001

Metabolic equivalent tasks

0.77

0.67–0.90

0.001

0.82

0.70–0.97

0.021
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